ClinicalTrials.gg
CompletedNCT02422030Updated Aug 8, 2017

CKD-337(2) Drug-drug Interaction Study

A Phase 1 interventional study of Lipitor Tab. 40mg and Trilipix 135mg in Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-08.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.

Read the detailed description

This study is a randomized, open-label, multiple dosing, 3-way crossover design to evaluate the drug-drug interaction between Atorvastatin (Lipitor) and Fenofibric (Trilipix) acid in healthy male subjects. Subjects will receive repeated dose of Atorvastatin (40mg*1Tab/day) or Fenofibric acid (135mg*1Cap/day) or Atorvastatin (40mg*1Tab/day)/Fenofibric acid (135mg*1Cap/day). Each treatment period was separated by a washout period of at least 8 days.

02

Conditions studied

  • Healthy

Keywords

  • Male Volunteers
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy man older than 19 years at the time of screening.
  • more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg
  • Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
  • Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as test.
  • Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
  • Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is (Except untreated asymptomatic seasonal allergies at the time of administration)
  2. Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
  3. Showing the value that corresponds to following laboratory parameters: or AST or CK > 2* .
  4. Alcohol > 210g/week, within 6 months prior to the screening.
  5. Taking the medication involved in other clinical trials within two months before the first dose medication characters.
  6. Sitting Systolic Blood Pressure ≥ 140 mmHg, Diastolic Blood Pressure ≥ 90 mmHg at the time of screening.
  7. History of alcohol or drug abuse, within 1 year
  8. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
  9. Smoker (> 20cigarettes/day)
  10. Subjects who takes ETC or OTC medicine within 10days before the first IP administration.
  11. Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.
  12. Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  13. Subject with serious history of or allergy to product.
  14. Active liver disease.
  15. Muscle disease.
  16. Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.
  17. Patients with severe hepatic impairment or Gallbladder Disease.
  18. Patients with moderate to severe renal impairment.
  19. Patients experienced allergy or phototoxicity during treatment with fibrate or ketoprofen.
  20. Subjects who is not able to comply with guidelines described in the protocol.
  21. Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group1: TreatmentA+TreatmentB+TreatmentC

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

  • Experimental
    Group2: TreatmentC+TreatmentA+TreatmentB

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

  • Experimental
    Group3: TreatmentB+TreatmentC+TreatmentA

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

  • Experimental
    Group4: TreatmentC+TreatmentB+TreatmentA

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

  • Experimental
    Group5: TreatmentB+TreatmentA+TreatmentC

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

  • Experimental
    Group6: TreatmentA+TreatmentC+TreatmentB

    TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

    Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg

Interventions

06

What researchers measure

Primary outcomes

  1. Atorvastatin and Fenofibric acid AUCτ

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

  2. Atorvastatin and Fenofibric acid Css,max

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

Secondary outcomes

  1. Atorvastatin and Fenofibric acid Css,min

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

  2. Atorvastatin and Fenofibric acid Css,av

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

  3. 2-hydroxyatorvastatin AUCτ

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

  4. 2-hydroxyatorvastatin Css,max

    1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points

    Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks

07

Study locations

1 site
  • Chonbuk National University Hospital
    Deokjin-gu, Jeonju-si, Jeollabuk-do 561-712, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Mar 2015, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2015
First posted
Apr 21, 2015
StartActual
Mar 17, 2015
Primary completionActual
Mar 22, 2015
CompletionActual
Apr 30, 2015
Last update
Aug 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02422030
Responsible party
Sponsor
First posted
Apr 21, 2015
Start date
Mar 17, 2015
Primary completion
Mar 22, 2015
Completion
Apr 30, 2015
Last update
Aug 8, 2017

Study contacts

Min Gul Kim
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Choline fenofibrate

Start the discussion